The pathological heterogeneity of Alzheimer’s disease (AD) necessitates a conceptual shift beyond the conventional amyloid and tau centric framework (Stockwell, 2022; Majernikova et al., 2024; Sun et al., 2023). Here, MAPT is linked to Alzheimer disease.